API
< Back to all clusters
[HEALTH] · United Kingdom, Spain, United States · 2 sources

started · updated

Medical experts emphasize early COPD diagnosis and anti-alarmin therapies

Medical experts are highlighting the importance of early diagnosis and new therapeutic approaches to improve outcomes for patients with chronic obstructive pulmonary disease (COPD). Experts, including professors from Imperial College London and the University of Barcelona, suggest that addressing underdiagnosis and late diagnosis is the most critical factor for improving patient outcomes over the next five years.

In addition to early intervention, research into anti-alarmin therapies is being explored to manage COPD exacerbations. Epithelial alarmins, such as interleukin 33 (IL-33) and thymic stromal lymphopoietin (TSLP), play a significant role in driving these exacerbations when triggered by viruses, bacteria, or pollutants. While clinical trials for anti-alarmin antibodies like itepekimab and astegolimab have shown varying results, these biologics represent a potential future direction for targeted treatment.

Entities

COPD · Imperial College London · Jadwiga A. Wedzicha · University of Barcelona · Àlvar Agustí